Managing Directors
Steven St. Peter, MD and Luke Evnin, PhD worked together at MPM Capital, where they invested in three successive venture capital funds. Each brings a successful track record of life sciences investing and organizational leadership, and both are excited to have reunited at Vie Ventures alongside Jeff Bluestone, PhD, a globally recognized leader in immunology and immune tolerance.
Together, Steven, Luke, and Jeff bring deep and complementary expertise in Immunology & Autoimmunity (I&A), including leadership across venture investing, academia, biotech company building, and patient-focused philanthropy. They are committed to leveraging these strengths and deep, personal networks with venture capital and public market investors to accelerate the development of innovative therapeutics.

Steven St. Peter, MD
Co-Founder & Managing Director
- Multiple successful investments and exits.
- Founder and CEO of Aratana Therapeutics through IPO and commercialization.
- Leader of one of the largest dedicated venture philanthropy funds.
2004–2012
Managing Director
MPM Capital
2012–2019
Founder, President & CEO
Aratana Therapeutics
2019–2025
Managing Director
T1D Fund
2025–Present
Co-founder and Managing Director
Vie Ventures

Luke Evnin, PhD
Co-Founder & Managing Director
- Created and built dozens of successful companies.
- Co-recipient of the Global Oncology Visionary Award.
- Three-plus decades of life-sciences venture investing.
1997–2023
Co-Founder & Managing Director
MPM Capital
2002–Present
Chairman
Scleroderma Research Foundation
2025–Present
Co-founder and Managing Director
Vie Ventures

Jeff Bluestone, PhD
Managing Director
- International leader in immune tolerance and regulatory T cells.
- Pioneer and thought leader for cells as medicines.
- Four-plus decades of scientific and translational leadership, including UCSF and the Immune Tolerance Network.
2015–2019
CEO & President
Parker Institute for Cancer Immunotherapy
2019–2025
Co-Founder & CEO
Sonoma Biotherapeutics
Present
Co-Founder
Monocacy Therapeutics
Present
Managing Director
Vie Ventures
Our team
Our team brings complementary experience in disease-community engagement, financial management, and investment operations.
Lou DeGennaro, PhD
Senior Advisor
Lou is the former CEO of the Leukemia and Lymphoma Society, and has been an advisor to Vie Ventures since fall 2024. Given the scientific and biological links between immuno-oncology and autoimmune disease, Lou's involvement is particularly useful and relevant. Lou is primarily focused on implementing and managing Vie Ventures' strategic collaborator relationships.
Shane Bates
Chief Financial Officer
Shane is a Founder and Partner at Bridge Alternatives, a leading alternative investment services platform. Supported by a team of professionals at Bridge Alternatives, Shane leads operations and serves as the CFO of Vie Ventures.
A team united by conviction.
We bring deep, complementary expertise across venture investing, academia, biotech company building, and patient-focused philanthropy.
Or email us directly at contact@vieventures.com.

